Harnessing the vascular protective effects of CREB: The SIK-CRTC-CREB pathway as a therapeutic target
Blood vessel disease includes any condition that affects the circulatory system. The cyclic AMP (cAMP) system controls many processes in the cells associated with blood vessel protection, and we know that the system does not work properly in blood vessel disease. Understanding more about the cAMP system may reveal new ways to prevent or treat blood vessel disease. Dr Mark Bond from the University of Bristol has found that a messenger molecule called CREB, which is inside the cells of artery walls, is important for blood vessel health. He has identified one way that the cAMP system and CREB protect blood vessels - through proteins called CRTCs that activate CREB and turn on genes that control growth, movement and survival of blood vessel cells. The BHF has awarded him a grant to develop and test new strategies that could be used to activate CRTC and harness the protective effects of cAMP to benefit people.
Project details
| Grant amount | £225,479 |
|---|---|
| Grant type | Project Grants |
| Application type | Project Grant |
| Start Date | 23 February 2015 |
| Duration | 3 years |
| Reference | PG/14/82/31126 |
| Status | Complete |
